![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Michielsen Dirk PJ Braeckman Johan G Denis Louis
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.12, Iss.6, 2011-04, pp. : 977-982
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Prostate cancer: abiraterone acetate beats cabazitaxel
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 667, 2012-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Hormonal treatment for prostate cancer
Expert Opinion on Investigational Drugs, Vol. 10, Iss. 3, 2001-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)